"Not if buy when and how?"
an unusually bold statement, and very "un-wolgen"
The second phase 3 is a learning from the EPP FDA procedure. The will file when 105 results are in. If the FDA is din doubt the 107 results will help confirm the treatment.
6000 patients in year 2 and a multiple in the following years.
A redefinition of the true value of cuv.
The new pricing of scenesee will be an interesting question.
Ann: SCENESSE in Vitiligo - A Global Update, page-6
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$9.44 |
Change
-0.290(2.98%) |
Mkt cap ! $473.1M | |||
| Open | High | Low | Value | Volume |
| $9.68 | $9.68 | $9.41 | $1.014M | 106.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 278 | $9.43 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $9.52 | 278 | 1 |
View Market Depth
| Last trade - 16.10pm 23/06/2025 (20 minute delay) ? |
| CUV (ASX) Chart |